And so another busy day has ended. We apologize for the disruption in service this evening, due to an appointment in the big city. However, we have returned to our usual routine and, in fact, hope to have a couple of interesting items tomorrow morning. We do not wish to tease, but one has to do with Vioxx and another concerns Provenge. Until the morning, there are these...
ImClone Hires Former J&J Exec As CEO (Yahoo/Reuters)
Alnylam Pharma Posts Wider Loss (TheStreet.com)
Biogen Names New CFO (Yahoo/Reuters)
Mannkind Plans New Financing (TheStreet.com)